Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway

Biochemical Journal

Volumn 424, Issue 3, 2009, Pages 449-458

  Chang, Ming Cheng ^a   Chen, Chi An ^a   Hsieh, Chang Yao ^a   Lee, Chien Nan ^a   Su, Yi Ning ^a   Hu, Yu Hao ^a   Cheng, Wen Fang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Apoptosis; Cancer; Mesothelin; Ovarian cancer; Paclitaxel; Phosphoinositide 3 kinase (PI3K)

Indexed keywords

APOPTOSIS; APOPTOTIC; BCL-2 FAMILY; CANCER TISSUES; CASPASES; CROSSING POINT; CYTOTOXIC DRUGS; CYTOTOXICITY ASSAYS; EXTRACELLULAR SIGNAL-REGULATED KINASE; FLOW-CYTOMETRIC ANALYSIS; HOECHST; IMMUNOBLOTTING; IMMUNOPRECIPITATIONS; INDUCED APOPTOSIS; MITOGEN ACTIVATED PROTEIN KINASE; OVARIAN CANCERS; PACLITAXEL; PHOSPHOINOSITIDE 3-KINASE; PROTEIN EXPRESSIONS; REAL-TIME PCR; REVERSE TRANSCRIPTION; SECRETED PROTEIN; TRANSFECTANTS; TYROSINE PHOSPHORYLATION;

AMINO ACIDS; ENZYME ACTIVITY; PHOSPHATASES; PHOSPHORYLATION; PROTEINS;

CELL DEATH;

CASPASE 3; CASPASE 7; MESOTHELIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN MCL 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; MEMBRANE GLYCOPROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 73149108613     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20082196     Document Type: Article

References (55)

1. Parkin, D. M., Pisani, P. and Ferlay, J. (1993) Estimates of the worldwide incidence of eighteen major cancers in 1985. Int. J. Cancer. 54, 594-606
2. Beard, C. M., Hartmann, L. C., Atkinson, E. J., O'Brien, P. C., Malkasian, G. D., Keeney, G. L. and Melton, 3rd, L. J. (2000) The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann. Epidemiol. 10, 14-23
3. Gonzalez-Diego, P., Lopez-Abente, G., Pollan, M. and Ruiz, M. (2000) Time trends in ovarian cancer mortality in Europe (1955-1993): effect of age, birth cohort and period of death. Eur. J. Cancer 36, 1816-1824
4. Pfleiderer, A. (1984) Diagnosis and staging of ovarian cancer. J. Cancer Res. Clin. Oncol. 107, 81-88
5. Scholler, N., Fu, N., Yang, Y., Ye, Z., Goodman, G. E., Hellstrom, K. E. and Hellstrom, I. (1999) Soluble member(s) of the mesothelin/ megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc. Natl. Acad. Sci. U.S.A. 96, 11531-11536
6. Hassan, R., Bera, T. and Pastan, I. (2004) Mesothelin: a new target for immunotherapy. Clin. Cancer Res. 10, 3937-3942
7. Bast, Jr, R. C., Klug, T. L., St John, E., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L. et al. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309, 883-887
8. Chen, R. H., Chang, M. C., Su, Y. H., Tsai, Y. T. and Kuo, M. L. (1999) Interleukin-6 inhibits transforming growth factor-β-induced apoptosis through the phosphatidylinositol 3-kinase/Akt and signal transducers and activators of transcription 3 pathways. J. Biol. Chem. 274, 23013-23019
9. Argani, P., Iacobuzio-Donahue, C., Ryu, B., Rosty, C., Goggins, M., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Jaffee, E., Yeo, C. J. et al. (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7, 3862-3868
10. Hippo, Y., Yashiro, M., Ishii, M., Taniguchi, H., Tsutsumi, S., Hirakawa, K., Kodama, T. and Aburatani, H. (2001) Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res. 61, 889-895
11. Frierson, Jr, H. F., Moskaluk, C. A., Powell, S. M., Zhang, H., Cerilli, L. A., Stoler, M. H., Cathro, H. and Hampton, G. M. (2003) Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum. Pathol. 34, 605-609
12. Cheng, W. F., Hung, C. F., Chai, C. Y., Chen, C. A., Lee, C. N., Su, Y. N., Tseng, W. Y., Hsieh, C. Y., Shih Ie, M., Wang, T. L. and Wu, T. C. (2007) Generation and characterization of an ascitogenic mesothelin-expressing tumor model. Cancer 110, 420-431
13. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L. and Davidson, M. (1996) Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin. Oncol. 23, 40-47
14. Ozols, R. F. (2000) Optimum chemotherapy for ovarian cancer. Int. J. Gynecol. Cancer 10, 33-37
15. Wang, T. H., Wang, H. S. and Soong, Y. K. (2000) Paclitaxel-induced cell death: where the cell cycle and apoptosis come together. Cancer 88, 2619-2628
16. Yamamoto, K., Kikuchi, Y., Kudoh, K. and Nagata, I. (2000) Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. J. Cancer Res. Clin. Oncol. 126, 168-172
17. Vikhanskaya, F., Marchini, S., Marabese, M., Galliera, E. and Broggini, M. (2001) p73α overexpression is associated with resistance to treatment with DNA-damaging agents in a human ovarian cancer cell line. Cancer Res. 61, 935-938
18. O'Gorman, D. M. and Cotter, T. G. (2001) Molecular signals in anti-apoptotic survival pathways. Leukemia 15, 21-34
19. Cheng, W. F., Huang, C. Y., Chang, M. C., Hu, Y. H., Chiang, Y. C., Chen, Y. L., Hsieh, C. Y. and Chen, C. A. (2009) High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br. J. Cancer 100, 1144-1153
20. Larionov, A., Krause, A. and Miller, W. (2005) A standard curve based method for relative real time PCR data processing. BMC Bioinformatics 6, 62
21. Gosland, M. P., Lum, B. L. and Sikic, B. I. (1989) Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells. Cancer Res. 49, 6901-6905
22. Liu, X., Li, P., Liu, P., Xiong, R., Zhang, E., Chen, X., Gu, D., Zhao, Y., Wang, Z. and Zhou, Y. (2008) The essential role for c-Ski in mediating TGF-β1-induced bi-directional effects on skin fibroblast proliferation through a feedback loop. Biochem. J. 409, 289-297
23. Kato, K., Shiga, K., Yamaguchi, K., Hata, K., Kobayashi, T., Miyazaki, K., Saijo, S. and Miyagi, T. (2006) Plasma-membrane-associated sialidase (NEU3) differentially regulates integrin-mediated cell proliferation through laminin- and fibronectin-derived signalling. Biochem. J. 394, 647-656
24. Akimoto, T., Kusano, E., Inaba, T., Iimura, O., Takahashi, H., Ikeda, H., Ito, C., Ando, Y., Ozawa, K. and Asano, Y. (2000) Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int. 58, 269-282
25. Hsiao, P. N., Chang, M. C., Cheng, W. F., Chen, C. A., Lin, H. W., Hsieh, C. Y. and Sun, W. Z. (2009) Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology 256, 83-91
26. Slee, E. A., Adrain, C. and Martin, S. J. (1999) Serial killers: ordering caspase activation events in apoptosis. Cell Death Differ. 6,b 1067-1074
27. Huang, C. Y., Cheng, W. F., Lee, C. N., Su, Y. N., Chien, S. C., Tzeng, Y. L., Hsieh, C. Y. and Chen, C. A. (2006) Serum mesothelin in epithelial ovarian carcinoma: a new screening marker and prognostic factor. Anticancer Res. 26, 4721-4728
28. Hellstrom, I., Raycraft, J., Kanan, S., Sardesai, N. Y., Verch, T., Yang, Y. and Hellstrom, K. E. (2006) Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol. Biomarkers Prev. 15, 1014-1020
29. Jhala, N., Jhala, D., Vickers, S. M., Eltoum, I., Batra, S. K., Manne, U., Eloubeidi, M., Jones, J. J. and Grizzle, W. E. (2006) Biomarkers in diagnosis of pancreatic carcinoma in fine-needle aspirates. Am. J. Clin. Pathol. 126, 572-579
30. Liebig, B., Brabletz, T., Staege, M. S., Wulfanger, J., Riemann, D., Burdach, S. and Ballhausen, W. G. (2005) Forced expression of ΔN-TCF-1B in colon cancer derived cell lines is accompanied by the induction of CEACAM5/6 and mesothelin. Cancer Lett. 223, 159-167
31. Swierczynski, S. L., Maitra, A., Abraham, S. C., Iacobuzio-Donahue, C. A., Ashfaq, R., Cameron, J. L., Schulick, R. D., Yeo, C. J., Rahman, A., Hinkle, D. A. et al. (2004) Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays. Hum. Pathol. 35, 357-366
32. Creaney, J., Christansen, H., Lake, R., Musk, A. B., de Klerk, N. and Robinson, B. W. (2006) Soluble mesothelin related protein in mesothelioma. J. Thoracic Oncol. 1, 172-174
33. Downward, J. (1995) Signal transduction: a target for PI(3) kinase. Nature 376, 553-554
34. Kennedy, S. G., Wagner, A. J., Conzen, S. D., Jordan, J., Bellacosa, A., Tsichlis, P. N. and Hay, N. (1997) The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 11, 701-713
35. Parrizas, M., Saltiel, A. R. and LeRoith, D. (1997) Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3′-kinase and mitogen-activated protein kinase pathways. J. Biol. Chem. 272, 154-161
36. Kohn, A. D., Kovacina, K. S. and Roth, R. A. (1995) Insulin stimulates the kinase activity of RAC-PK, a pleckstrin homology domain containing Ser/Thr kinase. EMBO J. 14, 4288-4295
37. Uehara, N., Matsuoka, Y. and Tsubura, A. (2008) Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells. Mol. Cancer Res. 6, 186-193
38. Givant-Horwitz, V., Davidson, B., Lazarovici, P., Schaefer, E., Nesland, J. M., Trope, C. G. and Reich, R. (2003) Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol. Oncol. 91, 160-172
39. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G. et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10, 105-115
40. Dai, Y., Rahmani, M., Pei, X. Y., Khanna, P., Han, S. I., Mitchell, C., Dent, P. and Grant, S. (2005) Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. Blood 105, 1706-1716
41. Blagosklonny, M. V., Giannakakou, P., el-Deiry, W. S., Kingston, D. G., Higgs, P. I., Neckers, L. and Fojo, T. (1997) Raf-1/Bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res. 57, 130-135
42. Haldar, S., Basu, A. and Croce, C. M. (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res. 57, 229-233
43. Ibrado, A. M., Liu, L. and Bhalla, K. (1997) Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res. 57, 1109-1115
44. Scatena, C. D., Stewart, Z. A., Mays, D., Tang, L. J., Keefer, C. J., Leach, S. D. and Pietenpol, J. A. (1998) Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J. Biol. Chem. 273, 30777-30784
45. L and Bak expression. Clin. Cancer Res. 3, 2039-2046
46. Jones, N. A., Turner, J., McIlwrath, A. J., Brown, R. and Dive, C. (1998) Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between Bax and Bak up-regulation and the functional status of p53. Mol. Pharmacol. 53, 819-826
47. Srivastava, R. K., Srivastava, A. R., Korsmeyer, S. J., Nesterova, M., Cho-Chung, Y. S. and Longo, D. L. (1998) Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell. Biol. 18, 3509-3517
48. Eltabbakh, G. H., Mount, S. L., Beatty, B., Simmons-Arnold, L. and Cooper, K. (2006) Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J. Surg. Oncol. 93, 379-386
49. Kimura, Y., Aoki, J., Kohno, M., Ooka, H., Tsuruo, T. and Nakanishi, O. (2002) P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel. Cancer Chemother. Pharmacol. 49, 322-328
50. Smith, V., Raynaud, F., Workman, P. and Kelland, L. R. (2001) Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Mol. Pharmacol. 60, 885-893
51. Bera, T. K. and Pastan, I. (2000) Mesothelin is not required for normal mouse development or reproduction. Mol. Cell. Biol. 20, 2902-2906
52. Breidenbach, M., Rein, D. T., Everts, M., Glasgow, J. N., Wang, M., Passineau, M. J., Alvarez, R. D., Korokhov, N. and Curiel, D. T. (2005) Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 12, 187-193
53. Huang, R. P., Hossain, M. Z., Huang, R., Gano, J., Fan, Y. and Boynton, A. L. (2001) Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int. J. Cancer. 92, 130-138
54. Hassan, R., Viner, J. L., Wang, Q. C., Margulies, I., Kreitman, R. J. and Pastan, I. (2000) Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma. J. Immunother. 23, 473-479
55. Schaner, M. E., Ross, D. T., Ciaravino, G., Sorlie, T., Troyanskaya, O., Diehn, M., Wang, Y. C., Duran, G. E., Sikic, T. L., Caldeira, S. et al. (2003) Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell. 14, 4376-4386